Zacks Research Issues Positive Forecast for EW Earnings

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Zacks Research raised their Q3 2025 EPS estimates for Edwards Lifesciences in a report released on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the medical research company will earn $0.61 per share for the quarter, up from their prior estimate of $0.60. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q4 2025 earnings at $0.63 EPS, Q2 2026 earnings at $0.66 EPS, Q3 2026 earnings at $0.70 EPS and FY2026 earnings at $2.75 EPS.

A number of other research firms have also weighed in on EW. Oppenheimer reissued an “outperform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Citigroup boosted their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday. Robert W. Baird decreased their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company dropped their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Finally, Barclays raised their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, December 2nd. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average price target of $78.65.

Edwards Lifesciences Stock Performance

NYSE EW opened at $73.32 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a 50 day simple moving average of $69.26 and a two-hundred day simple moving average of $74.19. The stock has a market capitalization of $43.24 billion, a PE ratio of 10.67, a P/E/G ratio of 3.63 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the firm earned $0.59 EPS. The business’s revenue was up 8.9% on a year-over-year basis.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently bought and sold shares of the company. Legacy Wealth Management LLC MS increased its holdings in shares of Edwards Lifesciences by 48.6% during the third quarter. Legacy Wealth Management LLC MS now owns 14,081 shares of the medical research company’s stock valued at $929,000 after acquiring an additional 4,605 shares in the last quarter. Franklin Resources Inc. increased its stake in Edwards Lifesciences by 2.3% during the 3rd quarter. Franklin Resources Inc. now owns 1,196,059 shares of the medical research company’s stock valued at $83,282,000 after purchasing an additional 27,193 shares in the last quarter. Peapack Gladstone Financial Corp raised its holdings in shares of Edwards Lifesciences by 108.0% in the third quarter. Peapack Gladstone Financial Corp now owns 293,758 shares of the medical research company’s stock worth $19,385,000 after buying an additional 152,539 shares during the last quarter. Tidal Investments LLC lifted its stake in shares of Edwards Lifesciences by 0.7% during the third quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company’s stock worth $2,609,000 after buying an additional 275 shares during the period. Finally, Destination Wealth Management grew its holdings in shares of Edwards Lifesciences by 2.8% during the third quarter. Destination Wealth Management now owns 7,012 shares of the medical research company’s stock valued at $463,000 after buying an additional 193 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,000 shares of company stock valued at $2,323,150. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.